Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.64 |
| ▸ | MTOR | P42345 | 4/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633129 | 0.78 | PIK3CA (0.67) | PIK3CAPIK3R1MTOR | |
| SCHEMBL893488 | 0.78 | PIK3CA (1.00) | PIK3CAPIK3R1PRKDC | |
| SCHEMBL632409 | 0.77 | PIK3CA (0.74) | PIK3CAPIK3R1CYP2C9 | |
| SCHEMBL632859 | 0.75 | PIK3CA (0.68) | PIK3CAPIK3R1MTOR | |
| SCHEMBL15603030 | 0.74 | PIK3CA (0.69) | PIK3CAPIK3R1MTOR | |
| SCHEMBL632322 | 0.74 | PIK3CA (0.73) | PIK3CAPIK3R1MTOR | |
| SCHEMBL632723 | 0.72 | PIK3CA (0.64) | PIK3CAPIK3R1MTOR | |
| SCHEMBL636112 | 0.72 | PIK3CA (0.58) | PIK3CAPIK3R1MTOR | |
| SCHEMBL15603022 | 0.72 | PIK3CA (0.67) | PIK3CAPIK3R1MTOR | |
| SCHEMBL13828581 | 0.72 | PIK3CA (0.56) | PIK3CAMTORGRIA1JAK2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419429-B1 | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | claimed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PIK3CA 2/4885PIK3R1 6/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.